3-醛基吲哚-5-甲酸甲酯 | 197506-83-5

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3-醛基吲哚-5-甲酸甲酯
• 中文别名: 3-甲醛-1氢吲哚-5甲酸甲酯；5-甲酸甲酯吲哚-3-甲醛；3-甲酰基吲哚-5-羧酸甲酯
• 英文名称: methyl 3-formylindole-5-carboxylate
• 英文别名: methyl 3-formyl-1H-indole-5-carboxylate
• CAS: 197506-83-5
• 化学式: C₁₁H₉NO₃
• mdl: MFCD00211075
• 分子量: 203.197
• InChiKey: UGLRSYDAOVKFIJ-UHFFFAOYSA-N

物化性质

• 沸点：
  404.4±25.0 °C(Predicted)
• 密度：
  1.341±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  温度：2-8℃，保持惰性气体氛围。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Formylindole-5-carboxylic acid methyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Formylindole-5-carboxylic acid methyl ester
CAS number: 197506-83-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H9NO3
Molecular weight: 203.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

3-醛基吲哚-5-甲酸甲酯是一种羧酸酯类衍生物，可用作医药化工中间体。

制备

3-醛基吲哚-5-甲酸甲酯作为吲哚-3-甲醛的衍生物还未见文献报道。本文根据化合物1的分子结构特点，采用3-甲基-4-硝基苯甲酸与乙醇进行酯化反应制得3-甲基-4-硝基苯甲酸甲酯（化合物2）。随后，化合物2与N,N-二甲基甲酰胺二乙基缩醛(DMFDEA)和哌啶缩合，并经铁粉和冰醋酸还原得到吲哚-5-甲酸甲酯。最后，通过Vilsmeier-Haack反应，利用三氯氧磷和N,N-二甲基甲酰胺合成化合物1。该工艺路线操作简便、收率高，适于工业化生产。

3-醛基吲哚-5-甲酸甲酯的合成路线图如下：

反应信息

• 作为反应物：
  描述：

  3-醛基吲哚-5-甲酸甲酯 在 盐酸 、 sodium tetrahydroborate 、 ammonium acetate 、 锌 作用下， 以 甲醇 、 水 为溶剂， 反应 2.5h， 生成 methyl 3-(2-aminoethyl)-1H-indole-5-carboxylate
  参考文献：
  名称：

  从吴茱萸碱中发现新型多环杂环衍生物用于治疗三阴性乳腺癌

  摘要：

  Evodiamine (Evo) 是一种在吴茱萸中发现的喹唑啉咔啉生物碱，具有中等的抗增殖活性。在此，我们报告了使用支架跳跃方法来鉴定一系列基于 Evo 的新型多环杂环衍生物作为拓扑异构酶 I (Top1) 抑制剂，用于治疗三阴性乳腺癌 (TNBC)，这是一种侵袭性乳腺癌亚型治疗选择有限的癌症。最有效的化合物7f抑制人乳腺癌细胞系 (MDA-MB-231) 中的细胞生长，IC 50值为 0.36 μM。进一步的研究表明，Top1 是7f的目标，直接诱导不可逆的Top1-DNA共价复合物形成或通过活性氧介导的间接机制诱导氧化性DNA损伤。更重要的是，体内研究表明，7f在 TNBC 患者来源的肿瘤异种移植模型中表现出有效的抗肿瘤活性。这些结果表明，化合物7f作为治疗 TNBC 的有希望的候选者值得进一步研究。

  DOI：

  10.1021/acs.jmedchem.1c01411
• 作为产物：
  描述：

  吲哚-5-羧酸 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三氯氧磷 作用下， 以 乙腈 为溶剂， 反应 1.08h， 生成 3-醛基吲哚-5-甲酸甲酯
  参考文献：
  名称：

  N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG

  摘要：

  该发明提供了与PPARG（PPARγ）结合亲和力高的分子实体，抑制激酶介导的，例如cdk5介导的PPARG磷酸化，但不对PPARG产生激动作用。该发明的化合物可用于治疗患有PPARG起作用的疾病的患者，如糖尿病、胰岛素抵抗、糖耐量受损、糖尿病前期、高血糖、高胰岛素血症、肥胖或炎症。在使用该发明的化合物治疗这些疾病的方法中，该化合物可以避免在接受该化合物的患者中产生明显体重增加、水肿、骨生长或形成受损、心肌肥大或上述任何组合的副作用。该发明还提供了化合物的制备方法、用于评估该发明的化合物作为非激动性PPARG结合化合物的生物测定方法，以及制药组合物。

  公开号：

  US20120309757A1

文献信息

• Facile Installation of 2-Reverse Prenyl Functionality into Indoles by a Tandem N-Alkylation-Aza-Cope Rearrangement Reaction and Its Application in Synthesis
  作者：Xiaobei Chen、Huaqiang Fan、Shilei Zhang、Chenguang Yu、Wei Wang

  DOI：10.1002/chem.201503355

  日期：2016.1.11

  approach to the preparation of synthetically and biologically important, but challenging, 2‐reverse quaternary‐centered prenylated indoles with high efficiency. Notably, unusual nonaromatic 3‐methylene‐2,3‐dihydro‐1H‐indole architectures, instead of aromatic indoles, are produced. Furthermore, the aza‐Cope rearrangement reaction proceeds highly regioselectively to give the quaternary‐centered reverse prenyl

  描述了空前的串联N-烷基化-离子氮杂-Cope（或Claisen）重排-水解反应，该反应容易得到的吲哚基溴化物与烯胺类化合物。由于这两个过程的复杂性，已经发现了操作上简单的N-烷基化和随后的微波辐照离子氮杂-Cope重排-水解过程。串联反应是高效制备合成和生物学上重要但有挑战性的2-反向季铵中心的烯丙基化吲哚的有力方法。值得注意的是，非寻常的非芳香族3-亚甲基-2,3-二氢-1 H产生了吲哚结构，而不是芳香族吲哚。此外，aza-Cope重排反应在区域上具有很高的选择性，从而产生了以季中心为中心的异戊二烯基官能团，该官能团通常通过报道的方法产生两种区域异构体的混合物。合成的非芳族3-亚甲基-2,3-二氢-1H-吲哚结构的合成值已被证明是有效合成结构多样的2-反向炔丙基化吲哚（如二氢吲哚，吲哚稠合的杜邦）的通用组成部分。和内酰胺，以及天然产物布鲁索林D。
• Anti-Cytokine Heterocyclic Compounds
  申请人：Goldberg Daniel

  公开号：US20060276496A1

  公开（公告）日：2006-12-07

  Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.

  杂环化合物及其类似物以及它们作为丝裂原活化蛋白激酶-2（MAPKAP-k2）抑制剂的用途，以及用于预防或治疗可以通过调节受试者中MAPKAP-K2活性来治疗或预防的疾病或紊乱的方法，以及包括这些MAPKAP-K2抑制剂的药物组合物和试剂盒。
• [EN] PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS<br/>[FR] MODULATEURS DE PPARG POUR LE TRAITEMENT DE L'OSTÉOPOROSE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2015161108A1

  公开（公告）日：2015-10-22

  The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

  本发明提供了一种治疗进行性骨病的方法，如骨质疏松症、佩吉特病、多发性骨髓瘤或甲状旁腺功能亢进症，包括向患有该病的患者施用有效量的非激动剂PPARG调节剂。
• Indole-Containing Amidinohydrazones as Nonpeptide, Dual RXFP3/4 Agonists: Synthesis, Structure–Activity Relationship, and Molecular Modeling Studies
  作者：Dongliang Guan、Md Toufiqur Rahman、Elaine A. Gay、Vineetha Vasukuttan、Kelly M. Mathews、Ann M. Decker、Alexander H. Williams、Chang-Guo Zhan、Chunyang Jin

  DOI：10.1021/acs.jmedchem.1c01081

  日期：2021.12.23

  reward. However, exploration of its therapeutic applications has been hampered by the lack of small molecule ligands and the cross-activation of RXFP1 in the brain and RXFP4 in the periphery. Herein, we report the first structure–activity relationship studies of a series of novel nonpeptide amidinohydrazone-based agonists, which were characterized by RXFP3 functional and radioligand binding assays.

  中枢松弛素 3/RXFP3 系统在压力反应、喂养和奖励动机中发挥重要作用。然而，由于缺乏小分子配体以及大脑中 RXFP1 和外周 RXFP4 的交叉激活，阻碍了对其治疗应用的探索。在此，我们报告了一系列新型非肽脒腙类激动剂的首次构效关系研究，其特征在于 RXFP3 功能和放射性配体结合测定。几种强效且有效的RXFP3激动剂(例如，10d )被鉴定为EC 50值<10 nM。这些化合物对 RXFP4 也具有高效力，但对 RXFP1 没有激动剂活性，表明 RXFP3/4 的选择性比 RXFP1 高 100 倍以上。体外ADME 和药代动力学评估显示脒腙衍生物可能具有有限的脑渗透性。总的来说，我们的研究结果为进一步优化先导化合物以开发合适的激动剂来探测大脑中的 RXFP3 功能提供了基础。
• [EN] BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF<br/>[FR] COMPOSÉS BENZOPYRAZOLE ET ANALOGUES DE CEUX-CI
  申请人：BIOCRYST PHARM INC

  公开号：WO2017136395A1

  公开（公告）日：2017-08-10

  Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof. The compounds are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising a compound of formula (I), and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by aberrant complement system activity.

  揭示了式（I）的化合物及其药学上可接受的盐。这些化合物是裂解系统的抑制剂。还提供了包含式（I）化合物的药物组合物，以及涉及使用这些化合物和组合物在治疗和预防由异常裂解系统活性特征的疾病和状况中的方法。